Clin2
NCT07058688Possibly a fitRecruiting

Testing a new drug for Alzheimer's (NTRX-07)

Alzheimer DiseaseMild Cognitive Impairment

Part of Brain & nervous system, Mental health clinical trials.

This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
48 people
Ages
65 years to 80 years
Study type
Interventional

Who can take part

  • Age 65 to 80 years old.
  • Has mild to moderate memory loss (confirmed by a short memory test).
  • A blood test or brain scan that suggests Alzheimer's (within the last 2 years).
  • Living at home with a caregiver who can help with study medicine and visit the clinic.
  • Stable on current Alzheimer's medications (no changes for 6 months).
  • No other major health problems like heart or liver disease, or a different cause for memory loss.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06995573Recruiting· Phase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness

This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.

Salzburg, State of Salzburg
NCT06761066Not yet recruiting
Testing NVP-NK4146 for mild cognitive impairment due to Alzheimer's

This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.

NCT04601038Recruiting· Phase 2
Testing a stress-blocking drug for early Alzheimer's risk

This study tests a new medication, CORT108297, that may help protect the brain from the harmful effects of stress in people at risk for Alzheimer's disease. It is looking for adults age 55 and older who either have mild memory problems or are healthy but have a family history, APOE4 gene, or memory concerns.

Baltimore, Maryland
NCT06885567Not yet recruiting· Phase 2
Testing BEY2153 for Early Alzheimer's Disease

This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.

Seoul
NCT06619613Recruiting· Phase 1
Study of CM383 for early Alzheimer's disease

This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.

Hefei
NCT06535308Recruiting· Phase 1
Testing a new Alzheimer's drug for moderate disease

This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.

Seoul, Jongno-gu

Hear when a new Mild Cognitive Impairment trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.